Women receiving kidneys from males donors are at a higher risk of organ rejection than those who received one from another woman, a new Swiss study says. Researchers now recommend that the gender of patients and donors should be considered in future operations to avoid such problems.

Researchers at University Hospital Basel analyzed data on 195,516 people in Europe who received kidneys from deceased donors between 1985 and 2004, and found that gender can substantially affect whether the operation will be successful

Pregnant women who consumed low levels of vitamin D during gestation are more likely to have babies who develop tooth enamel problems, which can lead to tooth decay, new Canadian research says.

Researchers at the University of Manitoba here studied 206 women for the vitamin D levels in their second trimester of pregnancy and found only 21 (10.5 percent) of the women had adequate levels of this sunshine vitamin, HealthDay news reported

Stanford University researchers have developed a method that can increase the ability to predict whether a woman will become pregnant through in vitro fertilization (IVF).

The new method would save time and money of thousands of infertile couples and help them decide whether investing in IVF procedure would yield any results for them

Women who gorge on junk food while pregnant could raise the risk of their offspring developing irreversible health problems such as obesity, high cholesterol and diabetes in adult life, according to new research.

Researchers at the Royal Veterinary College here carried out their study involving rats but scientists believe it also applies to humans. Rats that ate a diet rich in fat, sugar and salt while pregnant were more likely to give birth to offspring that had the tendency to over-eat and had a preference for junk food when compared to the offspring of rats given regular feed

Approval of GlaxoSmithKline PLC's cervical cancer vaccine Cervarix is expected to be delayed further after the drug maker decided to submit additional data to the U.S. Food and Drug Administration.

Glaxo decided that it will add results from an ongoing phase III study called HPV-008 to its original application in the first half of 2009 and a decision by the FDA is expected six months later. The 2007 application now under consideration included only data from an earlier trial